PL377472A1 - Bezwodny krystaliczny hemisiarczan pochodnej azydocytozyny - Google Patents

Bezwodny krystaliczny hemisiarczan pochodnej azydocytozyny

Info

Publication number
PL377472A1
PL377472A1 PL377472A PL37747203A PL377472A1 PL 377472 A1 PL377472 A1 PL 377472A1 PL 377472 A PL377472 A PL 377472A PL 37747203 A PL37747203 A PL 37747203A PL 377472 A1 PL377472 A1 PL 377472A1
Authority
PL
Poland
Prior art keywords
anhydrous crystalline
azido
derivative
cytosine hemisulfate
hemisulfate derivative
Prior art date
Application number
PL377472A
Other languages
English (en)
Other versions
PL213734B1 (pl
Inventor
Terrence Joseph Connolly
Joseph Armstrong Martin
Anthony Prince
Keshab Sarma
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL377472A1 publication Critical patent/PL377472A1/pl
Publication of PL213734B1 publication Critical patent/PL213734B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
PL377472A 2002-12-09 2003-12-08 Hemisiarczan 1-[4(S)-azydo-2 (S), 3(R)-dihydroksy-4-(hydroksymetylo)-1 (R)-cyklopentylo] cytozyny, sposób wytwarzania tego hemisiarczanu w polimorficznej postaci C, zastosowanie tego hemisiarczanu i srodek farmaceutyczny PL213734B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43188502P 2002-12-09 2002-12-09

Publications (2)

Publication Number Publication Date
PL377472A1 true PL377472A1 (pl) 2006-02-06
PL213734B1 PL213734B1 (pl) 2013-04-30

Family

ID=32507815

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377472A PL213734B1 (pl) 2002-12-09 2003-12-08 Hemisiarczan 1-[4(S)-azydo-2 (S), 3(R)-dihydroksy-4-(hydroksymetylo)-1 (R)-cyklopentylo] cytozyny, sposób wytwarzania tego hemisiarczanu w polimorficznej postaci C, zastosowanie tego hemisiarczanu i srodek farmaceutyczny

Country Status (32)

Country Link
US (1) US6864244B2 (pl)
EP (1) EP1572711B1 (pl)
JP (1) JP4563818B2 (pl)
KR (1) KR100675544B1 (pl)
CN (1) CN1314697C (pl)
AR (1) AR042312A1 (pl)
AT (1) ATE430755T1 (pl)
AU (1) AU2003292212B2 (pl)
BR (1) BR0317146A (pl)
CA (1) CA2506532C (pl)
CY (1) CY1109296T1 (pl)
DE (1) DE60327554D1 (pl)
DK (1) DK1572711T3 (pl)
ES (1) ES2324654T3 (pl)
GT (1) GT200300276A (pl)
HR (1) HRP20050503A2 (pl)
IL (1) IL168685A (pl)
JO (1) JO2542B1 (pl)
MX (1) MXPA05006044A (pl)
MY (1) MY130927A (pl)
NO (1) NO330454B1 (pl)
NZ (1) NZ540297A (pl)
PA (1) PA8590701A1 (pl)
PE (1) PE20040767A1 (pl)
PL (1) PL213734B1 (pl)
PT (1) PT1572711E (pl)
RU (1) RU2334756C2 (pl)
SI (1) SI1572711T1 (pl)
TW (1) TWI294882B (pl)
UY (1) UY28109A1 (pl)
WO (1) WO2004052906A1 (pl)
ZA (1) ZA200504472B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6731100A (en) * 1999-09-02 2001-04-10 Shionogi & Co., Ltd. Integrase inhibitors containing aromatic heterocycle derivatives
CA2284459C (en) 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
US20050182252A1 (en) * 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
WO2006021341A1 (en) * 2004-08-23 2006-03-02 F. Hoffmann-La Roche Ag Antiviral 4’-azido-nucleosides
AP2009004812A0 (en) * 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor
JP2010515680A (ja) 2007-01-05 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション Rna依存性rnaウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN103965116B (zh) * 2014-05-06 2016-06-15 中国科学院苏州纳米技术与纳米仿生研究所 半5-氟胞嘧啶盐、其制备方法及应用
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
CN115536710B (zh) * 2022-10-18 2024-04-16 南京工业大学 一种高品质胞苷硫酸盐晶体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449664A (en) * 1988-11-21 1995-09-12 Syntex (U.S.A.) Inc. Antiviral agents
AU4479189A (en) * 1988-11-21 1990-06-21 Syntex (U.S.A.) Inc. Antiviral agents
AU7623991A (en) * 1990-05-17 1991-11-21 Syntex (U.S.A.) Inc. Antiviral agents
ATE238328T1 (de) * 1996-10-16 2003-05-15 Ribapharm Inc Monozyklische l-nukleoside, analoga und ihre anwendungen
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
SK286630B6 (sk) * 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives

Also Published As

Publication number Publication date
UY28109A1 (es) 2004-06-30
MXPA05006044A (es) 2005-08-18
NZ540297A (en) 2007-05-31
AU2003292212A1 (en) 2004-06-30
PE20040767A1 (es) 2004-11-06
CN1314697C (zh) 2007-05-09
AU2003292212B2 (en) 2009-10-01
CA2506532A1 (en) 2004-06-24
WO2004052906A1 (en) 2004-06-24
AR042312A1 (es) 2005-06-15
RU2334756C2 (ru) 2008-09-27
PL213734B1 (pl) 2013-04-30
MY130927A (en) 2007-07-31
SI1572711T1 (sl) 2009-08-31
DE60327554D1 (de) 2009-06-18
DK1572711T3 (da) 2009-07-13
TW200502243A (en) 2005-01-16
KR100675544B1 (ko) 2007-01-30
HRP20050503A2 (en) 2006-12-31
NO330454B1 (no) 2011-04-18
ZA200504472B (en) 2006-02-22
JP2006510649A (ja) 2006-03-30
ATE430755T1 (de) 2009-05-15
CN1723215A (zh) 2006-01-18
NO20052732D0 (no) 2005-06-07
GT200300276A (es) 2004-09-02
KR20050084217A (ko) 2005-08-26
US6864244B2 (en) 2005-03-08
JP4563818B2 (ja) 2010-10-13
PT1572711E (pt) 2009-06-25
ES2324654T3 (es) 2009-08-12
BR0317146A (pt) 2005-10-25
EP1572711A1 (en) 2005-09-14
EP1572711B1 (en) 2009-05-06
PA8590701A1 (es) 2004-11-26
RU2005121927A (ru) 2006-01-27
US20040162265A1 (en) 2004-08-19
JO2542B1 (en) 2010-09-05
NO20052732L (no) 2005-09-06
TWI294882B (en) 2008-03-21
IL168685A (en) 2010-11-30
CY1109296T1 (el) 2014-07-02
HK1085483A1 (en) 2006-08-25
CA2506532C (en) 2011-09-20

Similar Documents

Publication Publication Date Title
IL168685A (en) Anhydrous crystalline azido cytosine hemisulfate derivative
ZA200410320B (en) Crystallization of sugars
PL377632A1 (pl) Przeciwwirusowe pochodne nukleozydów
GB2392653B (en) Subframe mount structure
GB0405884D0 (en) Modified nucleotides
ZA200406858B (en) Modified fluorinated nucleoside analoques
IL175702A0 (en) Nanoscale crystalline silicon-powder
AU2003301589A8 (en) Purine nucleosides
AU2003297594A8 (en) Crystalline form
TW569899U (en) Improved wrench rack
IL163780A0 (en) Crystalline parecoxib sodium
AU2003296601A8 (en) Antiviral nucleoside derivatives
AU2003289995A1 (en) Anhydrous crystalline form of valacyclovir hydrochloride
NO20044302L (no) Krystallinsk parecoxibnatrium
GB0228533D0 (en) Crystalline form
TW519023U (en) Structure improvement for wrench
TW557966U (en) Improved structure for drill screw
AU2003298204A1 (en) Adenosine derivative in polymorph v form
TW502688U (en) Improved structure for wrench rack
TW545498U (en) Improved mount structure
TW538921U (en) Improved structure for rear view mirror
TW519944U (en) Improved structure for tool rack
GB0303097D0 (en) Crystalline therapeutic agent
GB0321309D0 (en) Crystalline therapeutic agent
AU2351P (en) Spindrift Erigeron karvinskianus

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20131208